Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$18.96M+943.14%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Heather Getz
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 218
- Beta
- 1.36
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -13.22
Financials
Revenue
$18.96M+943.1%Net Income
$-9.30MEBITDA
$-7.10MFree Cash Flow
$-8.70MEPS (diluted)
$-0.16Shares Outstanding (diluted)
57.69M+19481.4%Operating Expenses
$17.61MCash & Debt
$22.66MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $80.28M | $-38.83M | $-0.83 |
| 2024 | $69.30M | $-37.84M | $-1.33 |
| 2023 | $58.45M | $-46.66M | $-2.04 |
| 2022 | $41.42M | $-44.30M | $-2.73 |
| 2021 | $29.46M | $-33.28M | $-2.30 |
| 2020 | $18.21M | $-28.79M | $-2.23 |
| 2019 | $15.45M | $-22.43M | $-2.26 |
| 2018 | $8.27M | $-21.09M | $-3.25 |
| 2017 | $4.25M | $-21.33M | $-3.29 |
Valuation
TELAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
107+33.33%Social Signal Score
Mentions (7)
- Newszacks.com·12d ago·Neutral
TELA Bio, Inc. (TELA) Reports Q3 Loss, Beats Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.
View source ↗ - Newsglobenewswire.com·16d ago·Negative
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 108,550 shares of its common stock to four newly-hired employees, with…
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
TELA Bio to Announce Third Quarter 2026 Financial Results MALVERN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2026 financial results on Tuesday, November 10, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results a…
View source ↗ - Newsseekingalpha.com·45d ago·Positive
TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·48d ago·Negative
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product.
View source ↗ - Newsglobenewswire.com·83d ago·Negative
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program
View source ↗ - Newsseekingalpha.com·103d ago·Positive
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Tue, Mar 23(in 4 months)
Consensus estimate $-0.16 per share
Typical surprise -13.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.13 vs $-0.16beat
- Mon, Aug 10$-0.20 vs $-0.17miss
- Tue, May 12$-0.21 vs $-0.14miss
- Wed, Mar 25$-0.16 vs $-0.18beat
- Thu, Nov 13$-0.19 vs $-0.17miss
- Mon, Aug 11$-0.22 vs $-0.18miss
Estimates and results for TELA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TELA officers and directors.
- Bought
- $4.2m
- Sold
- —
7 trades
0 trades
- Capper Joseph Hbought
- Capper Joseph Hbought
- Capper Joseph Hbought
- Capper Joseph Hbought
- Getz Heather Cbought
- Getz Heather Cbought
- Ew Healthcare Partners Fund 2, L.p.bought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TELA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
